Completed PHASE4 INTERVENTIONAL 2-arm NCT01709708

Use of the Tx360 Nasal Applicator in the Treatment of Chronic Migraine (Tx360)

Use of the Tx360 Nasal Applicator for Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine: A Double-blind Placebo-controlled Study

Sponsor: Clinvest

Conditions Chronic Migraine

Interventions Marcaine Saline

Updated 6 times since 2017 Last updated: Jan 25, 2018 Started: Sep 30, 2012 Primary completion: Feb 28, 2014 Completion: Feb 28, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01709708, this PHASE4 trial focuses on Chronic Migraine and remains completed. Sponsored by Clinvest, it has been updated 6 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Feb 2017 — Jun 2018 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Sep 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Clinvest
Tian Medical Inc.

Data source: Tian Medical Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ann Arbor, United States
• Springfield, United States